Form 4 for LENZ LENZ Therapeutics, Inc.
Accepted 2021-07-01 00:00:00 ET · period of report 2021-01-13 · accession 0000899243-21-027012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-07-01 | 2021-06-29 | LENZ | KARSEN PERRY A | Dir | C - Cnv Deriv | — | +8,126 | 164.0K | +5% | — |
| DM | 2021-07-01 | 2021-01-13+ | LENZ | KARSEN PERRY A | Dir | A - Grant | $0.883 | +113.3K | 18.7K | New | +$100.0K |
| D | 2021-07-01 | 2021-06-29 | LENZ | KARSEN PERRY A | Dir | C - Cnv Deriv | $0.00 | -19.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-06-29 | C | A | 8,126 | — | 164,034 | D | — | — | (F1) These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. |
| 2 | Derivative | Stock Option (right to buy) | 2021-01-13 | A | A | 74,794 | $0.00 | 74,794 | D | $0.3 · — to 2031-01-12 | 74,794 Common Stock | (F2) On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. (F4) 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of June 5, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase. |
| 3 | Derivative | Series B Preferred Stock | 2021-03-11 | A | A | 19,763 | $5.06 | 19,763 | D | — · — to — | 8,126 Common Stock | (F1) These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. |
| 4 | Derivative | Series B Preferred Stock | 2021-06-29 | C | D | 19,763 | $0.00 | 0 | D | — · — to — | 8,126 Common Stock | (F1) These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. |
| 5 | Derivative | Stock Option (right to buy) | 2021-03-17 | A | A | 18,698 | $0.00 | 18,698 | D | $6.11 · — to 2031-03-16 | 18,698 Common Stock | (F2) On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. (F5) 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. |